
dexketoprofen trometamol;
1 ampoule (2 ml solution for injection) contains dexketoprofen trometamol 73.8 mg, which is equivalent to dexketoprofen 50 mg
1 ml of solution for injection contains dexketoprofen trometamol 36.9 mg, which is equivalent to dexketoprofen 25 mg
injection solution
Administration and Dosages
Solution for intramuscular and intravenous administration.
Adults. The recommended dose is 50 mg with an interval of 8-12 hours. If necessary, a second dose should be administered after 6 hours. The maximum daily dose should not exceed 150 mg.
Elderly patients. Dose adjustment is usually not necessary.
Діти. Medicinal product should not be used by children and adolescents
See other features of application in medicinal product instruction for medical use.
Pharmacological group
Non-steroidal anti-inflammatory and anti-rheumatic drugs. Derivatives of propionic acid. Dexketoprofen. Code АТХ M01A E17.
Pharmacological properties
Dexketoprofen trometamol is a tromethamine salt (S)-(+)-2-(3- benzoylphenyl) propionic acid, which has an analgesic, anti-inflammatory and antipyretic effect and belongs to the class of non-steroidal anti-inflammatory medicines.
The mechanism of action of NSAIDs is based on reducing the synthesis of prostaglandins due to inhibition of cyclooxygenase activity.
See full details in medicinal product instruction for medical use.
Indications.
Symptomatic treatment of acute pain of medium and high intensity in cases where oral administration of the drug is impractical, for example in case of postoperative pain, renal colic and low back pain.
Contraindications.
III trimester of pregnancy and breastfeeding period.
Hypersensitivity to dexketoprofen, any other NSAIDs or to auxiliary substances of the medicinal product.
NSAIDs are contraindicated in patients with a history of hypersensitivity reactions (for example, bronchospasm, acute rhinitis or the development of nasal polyps, angioedema or urticaria) due to the use of ibuprofen, acetylsalicylic acid or other NSAIDs.
Active phase or history of peptic ulcer disease, gastrointestinal bleeding, or perforations.
History of gastrointestinal bleeding or perforation associated with prior NSAID therapy.
Gastrointestinal bleeding, other bleeding in the active phase or increased bleeding. Hemorrhagic diathesis and other blood coagulation disorders.
See other contraindications in medicinal product instruction for medical use.
See other features of application in medicinal product instruction for medical use.
Store in a dry place out of children reach at a temperature not exceeding 25 °С.
RC UA/19056/01/01